Company
Headquarters: Qingdao, China
Employees: 1,430
CN¥3.50 Billion
CNY as of Jan. 1, 2025
US$479.1 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Qingdao Vland Biotech INC. engages in the research and development of enzymes, probiotics, and animal vaccines and health products. It offers animal feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological products, such as live and inactivated poultry, and swine vaccines, as well as antibodies; poultry drugs comprising anti-parastic, antiviral, and nutritional drugs, as well as disinfectants; and traditional Chinese veterinary medicines for scale and avian breeding, livestock, and laying hens. It serves agriculture, animal husbandry, textile, paper making, household cleaning and detergents, food, biofuel, environmental protection, and other industries. The company was incorporated in 2005 and is headquartered in Qingdao, China. Qingdao Vland Biotech INC. operates as a subsidiary of Qingdao Kangdien Industrial Co., Ltd.
Qingdao Vland Biotech, Inc. has the following listings and related stock indices.
Stock: SSE: 603739 wb_incandescent